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Introduction
In vivo research is critical to the functional dissection of
multi-organ systems and whole organism physiology, and
the laboratory mouse remains a quintessential animal model
for studying mammalian, especially human, pathobiology.
Enabled by technological innovations in genome sequencing,
mutagenesis and genome editing, phenotype analyses, and
bioinformatics, in vivo analysis of gene function and dysfunc-
tion in the mouse has delivered new understanding of the
mechanisms of disease and accelerated medical advances.
However, many significant hurdles have limited the elucida-
tion of mechanisms underlying both rare and complex,
multifactorial diseases, leaving significant gaps in our scien-
tific knowledge. Future progress in developing a functionally
annotated genome map depends upon studies in model or-
ganisms, not least the mouse. Further, recent advances in
genetic manipulation and in vivo, in vitro, and in silico phe-
notyping technologies in the mouse make annotation of the
vast majority of functional elements within the mammalian
genome feasible. The implementation of a Deep Genome
Project—to deliver the functional biological annotation of all
human orthologous genomic elements in mice—is an essen-
tial and executable strategy to transform our understanding
of genetic and genomic variation in human health and dis-
ease that will catalyze delivery of the promised benefits of
genomic medicine to children and adults around the world.
Rationale
A comprehensive understanding of genetics, at the single
locus, gene, and genomic level, and the pathophysiological
consequences of gene variation resulting in gene, RNA, or
protein dysfunction are crucial to meeting societal expecta-
tions of precision medicine and critical to optimizing clin-
ical practice. With over 80% conserved synteny and a high
degree of gene orthology, the mouse and human genomes
have provided a unique opportunity for comparative func-
tional analysis and the use of genetically altered mice to in-
terrogate the pathobiology of human disease [1]. For
example, of the 6000–8000 rare genetic diseases cited by
the rare disease community, the genetic basis is known for
between 5000 and 6000 [2], many of which were revealed
and/or confirmed by studying the causative genetic variants
in mice. Nevertheless, when viewed from a genotype per-
spective, more than 75 to 80% of the computationally anno-
tated ~ 20,000 genes in the human genome have not had
variation in them tied to any specific phenotype [3].
CRISPR/Cas9 has enabled rapid and highly efficient tar-
geted mutagenesis of the mouse genome. Concurrent de-
velopment of in vivo analytical and imaging technologies
has transformed high-throughput pipelines for precise and
reproducible phenotyping of mouse mutants [4]. Deep phe-
notyping of virtually all body systems including cardiovas-
cular, digestive, endocrine, immune, integumentary,
lymphatic, muscular, neurological, sensory, reproductive,
respiratory, skeletal, and urinary systems is possible.
Further, online computational resources such as the MON-
ARCH Initiative (www.monarchinitiative.org) that use con-
trolled vocabularies to integrate numeric, text, and image
biological information from heterogeneous datasets (e.g.,
MGI, OMIM, Orphanet) link genotype to phenotype and
enable comparisons between mouse and human ontologies
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[5]. These and other advances have facilitated the coordin-
ation of industrial scale mutant mouse production and phe-
notyping at costs far less than previously imagined making
functional annotation of all human orthologous genomic
elements in mice an achievable scientific goal.
Realization of this goal is the foundation of the work of the
International Mouse Phenotyping Consortium (IMPC). The
IMPC is a coordinated program of 20 research laboratories
in 12 countries on 5 continents dedicated to the design, pro-
duction, and description of the function of human gene
orthologs in the mouse genome (www.mousephenotype.org).
The magnitude of this global effort reflects the spirit and
scale of the Human Genome Sequencing Project. The IMPC
uses homologous recombination in embryonic stem (ES)
cells and CRISPR/Cas9 technology to create mutants for
genes in the mouse genome followed by whole organism
phenotyping of female and male cohorts of adult mice and
embryos [6]. The focus thus far has been on the production
and phenotyping of null protein-coding alleles in the mouse
genome [7] recognizing that such resources serve as the fun-
damental baseline for mammalian gene function upon which
the generation and study of allelic series of other muta-
tions—hypomorphic, neomorphic, antimorphic, and hyper-
morphic—will prosper and will deliver further insights into
gene-phenotype relationships.
Gene association with a broad diversity of human dis-
eases, including hearing loss, ocular diseases, metabolic
disorders, bone pathologies, developmental abnormal-
ities, and others, differentiated by sex, has been revealed
through IMPC-led discovery research and IMPC-fueled
studies by the broader scientific community (https://
www.mousephenotype.org/data/publications). This work
continues on an industrial scale generating novel in-
sights into gene-based disease phenotypes and other sci-
entific domains such as conservation and ecology. This
combined mouse production, phenotyping, and inform-
atics approach has recently been applied to ~ 1/3 of
known Mendelian disease genes and detected significant
phenotypic similarities between human disease genes
and mouse knockouts (i.e., null alleles) of the orthologs
for approximately half the genes [8]. At least one clinical
phenotype per disease was tested for the majority (95%)
of the genes and matches detected across the whole
range of body systems [9].
Currently, IMPC has generated null mutations for
nearly 9000 genes of which over 6000 have been pheno-
typed. By July 2021, IMPC will complete comprehensive
phenotypic annotation for over 9000 genes, representing
about half of the ~ 18,000 human orthologs in the mouse
(Fig. 1). In its 10-year strategic plan for 2021–2030, the
IMPC calls for expanding mouse modeling studies to
inform precise molecular diagnostics and targeted thera-
peutics for Mendelian and multifactorial disorders to
maximize beneficial impacts on human health (https://
www.mousephenotypetest.org/about-impc/).
If revealing the full biological role of every gene is not
daunting enough, the pathobiological effects of individ-
ual human genetic and genomic variation further escal-
ate the challenge. As exome sequencing (ES), clinical
exome sequencing (cES), and whole genome sequencing
Fig. 1 IMPC phenotyping of mouse models of human orthologous genes. Outer ring: Of the 22,901 genes in the mouse genome, 18,000 are human
orthologs (blue) and 4901 are unique to the mouse (gray). Inner ring: There are currently 6255 genes (green) with phenotyping data of null alleles, and
another 2925 genes (yellow) will be phenotyped over the next 2 years, leaving ~ 9000 human orthologs (red) with no plans for either production or
phenotyping by the IMPC
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become more commonly used in research and medical
diagnostics to establish an etiologic molecular diagnosis,
the number of variants of unknown clinical significance
(i.e., VUS) is increasing exponentially and exceeding our
current capabilities to interpret loss-of-function alleles
[10]. Importantly, this growth has been driven not only by
clinical caregivers, but also by the growing diagnostic and
perceived personal utility of these advances by other stake-
holders including patients and patient families. Genetically
modified mice enable statistically powered, randomized,
and blinded experiments using sex-balanced and age-
matched cohorts of mutant mice alongside appropriate
genetic controls with sufficient sensitivity and specificity
to reliably assess gene function and dysfunction in relation
to specific traits, development, genetic context, and/or
other physical and environmental conditions. As a result,
the scale and breadth of mouse genetics research is
increasingly driving the use of mouse mutants and pheno-
typing data to inform human genomic diagnostic projects,
including the US NIH Centers for Mendelian Genomics
(www.mendelian.org), the Undiagnosed Diseases Network
(https://undiagnosed.hms.harvard.edu/), Canada’s Care4Rare
(http://care4rare.ca), The Gabriella Miller Kids First Pediatric
Research Program (https://kidsfirstdrc.org/), the Genomics
England Project (https://www.genomicsengland.co.uk/), and
the “Fondation Maladies Rares” (https://fondation-maladies-
rares.org/eng/). Animal model data, including mice, facilitate
the interpretation of potential causal variants among variants
of unknown significance in clinical sequencing.
Remaining gaps
Although substantial efforts to date have revealed a
fuller understanding of the functional landscape of the
entire mammalian genome, significant and important
knowledge gaps remain that limit the ability to interpret
the causal relationship of genes and genetic variations to
human development and disease. For instance, the ma-
jority of published gene to phenotype studies continue
to focus on genes that are well-annotated or for which
knowledge of biological function and pathological conse-
quences of mutations already exist [11]. As a result,
much of the human genome remains unexplored and
considered “dark” [12]. Strains of mouse mutants and as-
sociated phenotyping data are only available for approxi-
mately 60% of the mammalian genome, yet studies of
human genes are significantly primed and enhanced by
knowledge from model organisms [11]. Failure to fully il-
luminate the dark genome is a threat to realizing the full
potential of the science of genomics, clinical genomics,
the human genome project, and precision medicine. Over-
all, newly discovered disease genes significantly enhance
the molecular diagnosis rates for clinical exome sequen-
cing data by almost twofold [13]. Ambitious programs like
the IMPC that intentionally focus on comprehensive
phenotyping of genes with little to no functional annota-
tion directly address the dark genome crisis and offer the
potential for accelerated human health impact.
Only around 21% of the ~ 20,000 genes annotated on
the reference human genome have variation in them tied
to a human disease trait (Fig. 2). Further, although hu-
man and animal (mouse, rat, fly, fish, and worm) model
phenotypes together have been linked to ~ 80% of hu-
man genes, with mouse model phenotypes associated
with around 60% of human genes, the depth and extent
of phenotypic coverage for each gene is generally lim-
ited. Critically, for both human and model organisms,
our knowledge of pleiotropy and multi-morbidities is
often incomplete, undermining our understanding of
gene function and disease mechanisms. Moreover, our
knowledge of phenotypic heterogeneity and its poten-
tially underlying genetic bases (e.g., locus and allelic het-
erogeneity, multi-locus variation, modifier loci), as well
as our understanding of multiple disease phenotypes
converging on a single gene locus, age-dependent pene-
trance, and variable expressivity, are all limited. This lack
of in vivo functional annotation in experimental models
contributes to long diagnostic odysseys and is a signifi-
cant impediment to the development of molecular en-
tities targeted at specific gene products [14].
The significant progress that has been made in deci-
phering the genetic basis of rare monogenic diseases rep-
resents the low-hanging fruit of gene to phenotype
relationships. Progress in elucidating complex multi-allelic
and multi-locus relationships and the consequences of de
novo mutations in complex disorders is also dependent on
genome-wide functional descriptions and could be further
explored by the development of multi-allelic [15] and
multi-locus [16] models. Mouse models have already pro-
vided significant insight into complex diseases such as ju-
venile diabetes [17] and autism spectrum disorders [18].
Non-mouse models have and continue to contribute im-
mensely to this effort, but definitive identification of causal
relationships between mutant alleles and human diseases
will often require a mammalian model. The molecular,
cellular, and physiologic insights gained from mouse stud-
ies are critical to directly inform the early recognition of
predictive biomarkers before clinical symptoms manifest
and to drive the identification and validation of the new
therapeutic targets essential for precision medicine.
Moving forward
We postulate that four steps undertaken by the collect-
ive endeavors of the global community will be needed to
drive progress in genomic and precision medicine. These
four steps, allied to genome-wide goals for in vitro sys-
tems and other model organisms, will deliver a deeper
and more comprehensive understanding of individual
gene function, make biological resources and data
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available to experimentally decipher disease mechanisms,
interpret genomic variation, and reduce the diagnostic
odysseys of patients with variants of unknown signifi-
cance. The IMPC’s strategy 2021–2030 (https://www.
mousephenotype.org/wp-content/uploads/2019/05/
IMPC_Strategy_2021-30.pdf) is also formulated around
these four steps.
1) Complete functional annotation of the protein-
coding genome. Complete loss-of-function muta-
tions are essential for identifying the phenotypic im-
pact of protein-coding genes and a necessary first
step to interpreting clinically relevant human gen-
etic variation causing disease. By 2021, at the con-
clusion of the IMPC’s current mandate, ~ 9000
human orthologous genes in mice will remain to be
analyzed by the consortium. Stopping at this point,
halfway through the genome, would be equivalent
to the Human Genome Project halting its sequen-
cing effort after assembling euchromatic sequence
of just 11 chromosomes. It will be vital to continue
efforts toward the completion of the functional ana-
lysis of the remaining unannotated protein-coding
genes using mouse models.
2) Establish functional evaluation of the noncoding
genome. The entire coding region is only 3–5% of
the mammalian genome. The remaining 95% of the
genome plays many roles across a variety of
biological processes, including DNA replication,
transcriptional regulation, and genomic structure.
Of particular note, variation in enhancers, silencers,
promoters, and insulators can have significant
impact on both normal and abnormal gene
expression [19] and gene dosage phenomena [20].
Strategies must be implemented for the prioritization
and modeling of mutations of conserved noncoding
elements in order to fully explore the in vivo
function of the darkest part of the genome.
3) Translate functional biological knowledge to clinical
knowledge. The emerging field of genomic and
precision medicine relies on the ability to interpret
the potential pathophysiological consequences of
genetic variation in patients. Beyond academic and
research considerations, the long-term financial in-
vestments in translating human genetic variation to
functional phenotypes and disease mechanisms is
enormous and growing. Global investments from
government agencies and corporate investors are
Fig. 2 Proportion of human protein coding genes with known genotype to phenotype associations from human and a fish, rat, worm, mouse,
fly, and yeast model organisms or b mouse alone. As described in the text, the depth of phenotypic coverage does not match the breadth of
coverage enabled by model organisms. Human phenotypes are taken from known OMIM, Orphanet, and Clinvar Mendelian disease associations
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predicted to nearly triple from US$79billion to over
US$200billion in 10 years (https://bisresearch.com/
industry-report/precision-medicine-market.html).
For example, programs from the US All of Us Pro-
ject, UK Biobank, the UK 100K Genome Project,
the Chinese Precision Medicine Initiative, and many
others are enrolling volunteers in efforts to gather
personal history, clinical information, genome se-
quences, and environmental metadata to under-
stand the role of genes in health and disease in
order to identify new targets for molecular therap-
ies. For these investments to deliver on their prom-
ise to improve health outcomes from molecular
diagnosis to management and therapeutic interven-
tion, it will be necessary to integrate gene function
data generated from the study of mouse and other
animal models into clinical databases, such as Clin-
Var, ClinGen, and others. Continued development of
model organism databases, along with improvements
in data integration and analysis, is needed to enable
mechanistic insight into genetic variation and dis-
ease and support future developments in genomic
and precision medicine.
4) Enable rapid functional assessment of genomic
variation and integrate functional testing into the
clinical decision-making process. While statistical
inference of human patient data is currently used to
discriminate disease causing from benign associated
variants, a definitive molecular diagnosis is often
not attainable. Even in those cases where this
approach is sufficient, the delay in diagnosis is
costly—psychologically, socially, and economically.
It will be necessary to undertake programs for the
rapid creation and analysis of mouse models of
human coding variants along with more efficient
approaches to phenotyping. These models, along
with other mutational variants, will inform
diagnostic decisions and targeted treatments. With
these programs in place, clinicians and their
research colleagues could rely on mouse models as
diagnostic and therapeutic testing platforms,
examine the pathological significance of a genetic
variant in an orthologous mammalian system,
interrogate gene/phenotype relationships for
different types of alleles (e.g., SNV, etc.), explore
potential gene/environment effects, and access
comprehensive datasets to help guide clinical
decision-making. In turn, mouse genetic experts will
need to respond quickly with targeted phenotyping
of mouse models in order for them to achieve clin-
ical utility. It will be necessary to optimize funding
and bring scientific insights from mouse functional
data to inform the application of mouse models as
human patient avatars, make the knowledge gained
from mouse data available via the electronic med-
ical record, and enhance education and training of
clinicians in genetics and genomic medicine.
Conclusion
Despite the incredible scientific advances in genetics at
the single gene and genomic level, the collective biomed-
ical community has only begun to scratch the surface of
knowledge about the diverse and varied in vivo patho-
biological roles of functional elements throughout the
human genome. The global mouse genetics community
is primed to address the grand challenges that we face to
fully comprehend the role of genes and genetics in de-
velopment, biological homeostasis, systems biology, dis-
ease, and medicine, and is ready to launch a new era for
the systematic study of the function of the mammalian
genome. The time is right to embark on a Deep Genome
Project, on the scale of the Human Genome Project, that
will fundamentally enhance the knowledgebase across
the biomedical sciences. Driven by the enormous poten-
tial of mouse genetics and allied to developments in
other model organisms and in vitro approaches, this
project will be transformative for biology, medicine, and
global health.
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